Controlled release microparticles for vaccine development.
The primary and secondary sera IgG antibody responses to ovalbumin (OVA) entrapped in biodegradable poly(lactide-co-glycolide) (PLGA) microparticles were compared with the responses obtained with soluble OVA. In addition, OVA in PLGA microparticles was also administered after dispersion in an immunostimulatory vehicle, Freund's incomplete adjuvant (FIA). The primary IgG responses to OVA in microparticles/FIA were significantly greater than the responses to soluble OVA from day 14 to day 42, when booster immunizations were administered. From day 49 to the end of the study at day 84, the responses to OVA, both in microparticles alone and in microparticles/FIA, were significantly greater than the responses to soluble OVA. Nevertheless, the responses obtained for OVA in microparticles or microparticles/FIA were, in general, not as high as those obtained with OVA in Freund's complete adjuvant.
O'Hagan
D T
DT
Department of Pharmaceutical Sciences, University of Nottingham, University Park, UK.
Jeffery
H
H
Roberts
M J
MJ
McGee
J P
JP
Davis
S S
SS
D000818:Animals; D003692:Delayed-Action Preparations; D004797:Enzyme-Linked Immunosorbent Assay; D005620:Freund's Adjuvant; D007117:Immunization, Secondary / Q000379:methods; D007074:Immunoglobulin G / Q000032:analysis; D007279:Injections, Subcutaneous; D019344:Lactic Acid; D008297:Male; D008863:Microspheres; D010047:Ovalbumin / Q000008:administration & dosage*; D011100:Polyglycolic Acid; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers; D051381:Rats; D011919:Rats, Inbred Strains; D014612:Vaccines / Q000008:administration & dosage*
D003692:Delayed-Action Preparations; D007074:Immunoglobulin G; D011108:Polymers; D014612:Vaccines; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D010047:Ovalbumin; D005620:Freund's Adjuvant